[go: up one dir, main page]

US20030017215A1 - Cancer treatment composition and method using natural plant essential oils with signal transduction modulators - Google Patents

Cancer treatment composition and method using natural plant essential oils with signal transduction modulators Download PDF

Info

Publication number
US20030017215A1
US20030017215A1 US09/455,543 US45554399A US2003017215A1 US 20030017215 A1 US20030017215 A1 US 20030017215A1 US 45554399 A US45554399 A US 45554399A US 2003017215 A1 US2003017215 A1 US 2003017215A1
Authority
US
United States
Prior art keywords
plant essential
pharmaceutical composition
essential oil
oil compound
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/455,543
Other languages
English (en)
Inventor
Steven M. Bessette
Essam E. Enan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecosmart Technologies Inc
Original Assignee
Ecosmart Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecosmart Technologies Inc filed Critical Ecosmart Technologies Inc
Priority to US09/455,543 priority Critical patent/US20030017215A1/en
Assigned to ECOSMART TECHNOLOGIES, INC. reassignment ECOSMART TECHNOLOGIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BESSETTE, STEVEN M., ENAN, ESSAM E.
Assigned to AMSOUTH BANK reassignment AMSOUTH BANK SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ECOSMART TECHNOLOGIES, INC.
Assigned to CARELL, JAMES W. reassignment CARELL, JAMES W. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ECOSMART TECHNOLOGIES, INC.
Assigned to AMSOUTH BANK reassignment AMSOUTH BANK FULL RELEASE OF SECURITY INTEREST Assignors: ECOSMART TECHNOLOGIES, INC.
Publication of US20030017215A1 publication Critical patent/US20030017215A1/en
Assigned to ECOSMART TECHNOLOGIES, INC. reassignment ECOSMART TECHNOLOGIES, INC. FULL RELEASE OF SECURITY INTEREST RECORDED ON FEBRUARY 26, 2002 AT REEL/FRAME 012418/0824. Assignors: CARELL, JAMES W.
Priority to US10/770,386 priority patent/US7008649B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates, in general, to therapeutically effective pharmaceutical compositions containing plant essential oil compounds, with one or more signal transduction modulators and methods for using same for prophylactically or therapeutically treating soft tissue cancer in mammals, including humans, such as, for example, breast cancer.
  • Breast cancer is a proliferative disease of mammary epithelial cells and estrogen has been shown to stimulate cell proliferation of these cells both in culture and in mice (Soto and Sonnenschein, 1985; Osborne, 1988).
  • Xenoestrogens have been proposed to stimulate cell proliferation through binding and activating estrogen receptors (ERs) (Miller et al., 1993; Hoffman, 1992).
  • ERs estrogen receptors
  • the incidence of breast cancer has been steadily rising during the past two or three decades, a trend characterized by increasing rates among estrogen-responsive tumors, by continuing increases among older women, and by growing numbers in both developed and developing countries (Harris et al., 1992).
  • An object of the present invention is to provide novel compositions that contain certain plant essential oil compounds, natural or synthetic, or mixtures or derivatives thereof, with one or more signal transduction modulators, as prophylactic for, and treatment of, soft tissue cancer.
  • the present invention is directed to novel pharmaceutical compositions containing plant essential oils, including mixtures or derivatives thereof, which are synthetically made or obtained from natural sources, containing signal transduction modulators.
  • the present invention is directed to a pharmaceutical composition for the prevention or treatment of soft tissue cancer in mammals, comprising a pharmaceutically effective amount of at least one plant essential oil compound and at least one signal transduction modulator in admixture with a pharmaceutically acceptable carrier.
  • the present invention is also directed to methods for using such novel pharmaceutical compositions for prophylactically or therapeutically treating soft tissue cancers.
  • FIG. 1 shows the concentration-response of plant essential oil compounds against E 2 -induced growth in breast cancer cells.
  • FIG. 2 shows the effect of cAMP inducer, forskolin (FK), and c-Src kinase inhibitor, geldanamycin (GM) on E 2 -induced proliferation in breast cancer cells.
  • FIG. 3 shows the effect of mixed exposure of plant essential oil compounds and cAMP inducer forskolin (FK) on E 2 -induced breast cancer cell growth.
  • FIG. 4 shows the effect of c-Src kinase inhibitor, geldanamycin (GM) on the antiestrogenic activity of plant essential oil compounds against E 2 -induced growth in breast cancer cells.
  • FIG. 5 shows the mixed exposure effect of okadaic acid (OA) (a serine/threonine protein phosphatase inhibitor) and plant essential oil compounds on the growth of breast cancer cells in the presence and absence of E 2 .
  • OA okadaic acid
  • the present invention provides a novel pharmaceutical composition
  • a novel pharmaceutical composition comprising at least one plant essential oil compound derived from either natural or synthetic sources and at least one signal transduction modulator including mixtures or derivatives of plant essential oil compound.
  • the specific plant essential oils disclosed herein or derivative thereof comprise a monocyclic, carbocyclic ring structure having six-members and substituted by at least one oxygenated or hydroxyl functional moiety.
  • plant essential oils encompassed within the present invention include members selected from the group consisting of aldehyde C16 (pure), alpha-terpineol, amyl cinnamic aldehyde, amyl salicylate, anisic aldehyde, benzyl alcohol, benzyl acetate, cinnamaldehyde, cinnamic alcohol, ⁇ -terpineol, carvacrol, carveol, citral, citronellal, citronellol, p-cymene, diethyl phthalate, dimethyl salicylate, dipropylene glycol, eucalyptol (cineole), eugenol, isoeugenol, galaxolide, ger
  • the above plant essential oil compounds can also be administered in combination with at least one signal transduction modulator.
  • signal transduction modulators include members selected from the group consisting of cyclic adenosine monophosphate (cAMP)/cAMP-dependent protein kinase, tyrosine kinase, calcium phospholipid-dependent protein kinase (PKC), mitogen activated protein kinase family members, calcium-calmodulin-dependent protein kinase, and growth factor receptor inhibitors.
  • Specific non-limiting examples of such signal transduction modulators include octopamine, forskolin, PD98059, geldanamycin and genistein, and staurosporin.
  • the above plant essential oil compounds and signal transduction modulators of the present invention may be purchased from conventional sources, may be readily isolated from specific plants or trees and purified (isolated) or may be synthesized using conventional techniques.
  • these compounds may be conveniently synthesized from readily available starting materials.
  • the relative ease with which the compositions of the present invention can be synthesized represents an enormous advantage in the large-scale production of these compounds.
  • the therapeutically-active plant essential oil compounds of the present invention may be modified or derivatized by appending appropriate functionalities, i.e., functional groups, to enhance selective biological properties.
  • modifications are known in the art and include those that increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • the plant essential oil compounds may be altered to pro-drug form such that the desired therapeutically-active form of the compound is created in the body of the patient as the result of the action of metabolic or other biochemical processes on the pro-drug.
  • pro-drug forms include ketal, acetal, oxime, and hydrazone forms of compounds which contain ketone or aldehyde groups.
  • the therapeutically-effective plant essential oil compounds or derivatives thereof of the present invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
  • Each stereogenic carbon may be of the R or S configuration. All such isomeric forms of these compounds are expressly included within the purview of the present invention.
  • compositions and method of the present invention include pharmaceutical compositions that comprise at least one plant essential oil, and pharmaceutically acceptable salts thereof, in combination with any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a patient, together with a plant essential oil compound of the present invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
  • Pharmaceutically acceptable salts of the plant essential oil compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include, without limitation, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, o
  • Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N—(C 14 alkyl)4+salts.
  • alkali metal e.g., sodium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., ammonium
  • N—(C 14 alkyl)4+salts e.g., sodium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., sodium
  • N—(C 14 alkyl)4+salts e.g., sodium
  • pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d.alpha-tocopherol polyethyleneglycol 1000 succinate, or other similar polymeric delivery matrices or systems, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene
  • Cyclodextrins such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-.beta.-cyclodextrins, or other solublized derivatives may also be advantageously used to enhance delivery of therapeutically-effective plant essential oil compounds and signal transduction modulators of the present invention.
  • compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, however, oral administration or administration by injection is preferred.
  • the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.
  • compositions of the present invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • compositions of the present invention may also be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • topical administration of the pharmaceutical compositions of the present invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
  • compositions of this invention may be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
  • Another acceptable pharmaceutical preparation would be an encapsulated form of the plant essential oils, as is, or modified as per the prior descriptions.
  • the walls of the capsules could be designed to release the plant essential oils rapidly, i.e. one minute, hour or day, or it could be designed to release over some designated period of time, i.e. days, weeks or months.
  • the wall materials could be natural or synthetic polymers acceptable to the US FDA or composed of lipids or other suitable materials.
  • These capsules could be delivered either orally or by injection and could be either water or oil based depending upon the desired method of use or required rate of release.
  • Dosage levels of between about 0.001 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the active ingredient compound are useful in the prevention and treatment of soft tissue cancers.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w).
  • such preparations contain from about 20% to about 80% active compound.
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • the prophylactic use of the present invention may require the daily intake of a prophylactically-effective amount.
  • compositions and methods of the present invention will be further illustrated in the following, non-limiting Examples.
  • the Examples are illustrative of various embodiments only and do not limit the claimed invention regarding the materials, conditions, weight ratios, process parameters and the like recited herein.
  • the Examples show, inter alia, that certain signal transduction modulators synergize the anti-estrogenic activity of plant essential oil compounds against estrogen (E 2 )-induced abnormal cell growth in human epithelial breast cancer cells.
  • E 2 estrogen
  • MCF-7 cells were cultured in growth medium supplemented with 10% fetal bovine serum (FBS). At 85% confluence, cells were sub-cultured in 6 well petri-dishes and supplemented with 5% FBS serum stripped medium, phenol red free for 24 hours prior to the treatment of different concentrations of the test chemicals. After 5 days of treatment cells were trypsinized and collected using an Eppendorf microcentrifuge. The cell pellets were resuspended in 1% trypan blue.
  • FBS fetal bovine serum
  • FIG. 1 shows that there is a dose-response dependent relationship between plant essential oil compounds and their antiestrogenicity against E 2 -induced abnormal cell growth in human epithelial breast cancer cells (MCF-7).
  • MCF-7 human epithelial breast cancer cells
  • This Example shows the mixed exposure effect of plant essential oil compounds and signal transduction modulators, particularly, cAMP/PKA activator (forskolin, FK) and tyrosine kinase family member, c-Src kinase (p src60 ), inhibitor, geldananmycin on E 2 -induced cell growth.
  • MCF-7 cells were cultured in growth medium supplemented with 10% fetal bovine serum (FBS). At 85% confluence, cells were sub-cultured in 6 well petri-dishes medium supplemented with 5% FBS serum stripped medium, phenol red free for 24 hours prior to the treatment of different concentrations of the test chemicals.
  • FBS fetal bovine serum
  • Cells were either counted (5 days after treatment) or used to determine cell proliferation (24 hr after treatment) using 3 H-thymidine incorporation. To count the cell, cells were trypsinized, and collected using Eppendorf microcentrifuge. The cell pellets were resuspended in 1% trypan blue and three aliquots (10 ul each) of the viable cell suspension was counted using a haemocytometer assay. Each sample was then counted three times to obtain an average count. For thymidine incoroporation, 24 hr after cell treated with test mixture, cells were incubated with 1 uCi 3 H-thymidine.
  • ER estrogen receptor
  • FK 5 ⁇ M FK 5 ⁇ M
  • FIG. 3 demonstrates the interaction of FK with certain plant essential oil compounds.
  • FK does not appear to act as a synergist for all of the tested plant essential oil compounds.
  • the data shows that FK synergizes the antiestrogenic activity of eugenol and cinnamic aldehyde, but not thymol or isoeugenol, which suggests that chemical structure is important to the synergistic activity of FK against cell proliferation.
  • FIG. 4 shows the involvement of a tyrosine kinase family member, c-Src kinase, in the growth of breast cancer cells.
  • GM (10 ng/ml), the c-Src kinase inhibitor, potentiates the antiestrogenic activity of E 2 -on cell growth.
  • GM also synergizes the antiestrogenic activity of eugenol against E 2 induced cell growth.
  • This Example shows the mixed exposure effect of plant essential oil compounds and signal transduction modulators, serine/threonine phosphatase inhibitor, okadaic acid (OA), on Human Epithelial Breast Cancer Cells (MCF-7).
  • MCF-7 cells were cultured in growth medium supplemented with 10% fetal bovine serum (FBS). At 85% confluence, cells were sub-cultured in 6 well petri-dishes medium supplemented with 5% FBS serum stripped medium, phenol red free for 24 hours prior to the treatment of 10 ug/ml of each plant essential oil compound and 1 nM okadiac acid. After 24 hr treatment, cells were used to determine cell proliferation using 3 H-thymidine incorporation.
  • FBS fetal bovine serum
  • FIG. 5 shows that protein phosphatase(s) is involved in the biological activity of E 2 .
  • the action of OA is highly expressed in the absence of E 2 .
  • OA synergies the antiestrogenic activity of thymol only in the absence of E 2 .
  • OA synergies the antiestrogenic action of eugenol regardless of the absence or presence of E 2 .
  • one or more signal transduction modulators may be used in combination with plant essential oil compounds and derivatives thereof to provide anti-proliferative, anti-estrogenic and/or anti-mitogenic compositions for prophylactically and/or therapeutically treating soft tissue cancers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US09/455,543 1998-12-07 1999-12-07 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators Abandoned US20030017215A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/455,543 US20030017215A1 (en) 1998-12-07 1999-12-07 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US10/770,386 US7008649B2 (en) 1998-12-07 2004-02-04 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11127198P 1998-12-07 1998-12-07
US09/455,543 US20030017215A1 (en) 1998-12-07 1999-12-07 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/770,386 Division US7008649B2 (en) 1998-12-07 2004-02-04 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators

Publications (1)

Publication Number Publication Date
US20030017215A1 true US20030017215A1 (en) 2003-01-23

Family

ID=22337523

Family Applications (8)

Application Number Title Priority Date Filing Date
US09/455,543 Abandoned US20030017215A1 (en) 1998-12-07 1999-12-07 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US09/455,542 Abandoned US20020182268A1 (en) 1998-12-07 1999-12-07 Cancer treatment compositions and method using natural plant essential oils
US10/190,667 Expired - Fee Related US6812258B2 (en) 1998-12-07 2002-07-09 Cancer treatment composition and method using natural plant essential oils
US10/274,963 Abandoned US20030108622A1 (en) 1998-12-07 2002-10-22 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
US10/274,964 Abandoned US20030108623A1 (en) 1998-12-07 2002-10-22 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
US10/759,177 Expired - Fee Related US7291650B2 (en) 1998-12-07 2004-01-20 Cancer treatment composition and method using natural plant essential oils
US10/770,386 Expired - Fee Related US7008649B2 (en) 1998-12-07 2004-02-04 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US11/849,072 Abandoned US20080015249A1 (en) 1998-12-07 2007-08-31 Cancer treatment compositions and method using natural plant essential oils

Family Applications After (7)

Application Number Title Priority Date Filing Date
US09/455,542 Abandoned US20020182268A1 (en) 1998-12-07 1999-12-07 Cancer treatment compositions and method using natural plant essential oils
US10/190,667 Expired - Fee Related US6812258B2 (en) 1998-12-07 2002-07-09 Cancer treatment composition and method using natural plant essential oils
US10/274,963 Abandoned US20030108622A1 (en) 1998-12-07 2002-10-22 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
US10/274,964 Abandoned US20030108623A1 (en) 1998-12-07 2002-10-22 Cancer treatment composition and method using signal transduction modulators and natural plant essential oils as synergists for conventional treatments
US10/759,177 Expired - Fee Related US7291650B2 (en) 1998-12-07 2004-01-20 Cancer treatment composition and method using natural plant essential oils
US10/770,386 Expired - Fee Related US7008649B2 (en) 1998-12-07 2004-02-04 Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US11/849,072 Abandoned US20080015249A1 (en) 1998-12-07 2007-08-31 Cancer treatment compositions and method using natural plant essential oils

Country Status (24)

Country Link
US (8) US20030017215A1 (es)
EP (3) EP1137425A1 (es)
JP (3) JP2002531512A (es)
KR (1) KR20010080692A (es)
CN (1) CN100448454C (es)
AR (3) AR020019A1 (es)
AT (1) ATE307601T1 (es)
AU (3) AU1841900A (es)
BR (1) BR9916879A (es)
CA (3) CA2353475A1 (es)
CZ (1) CZ20011979A3 (es)
DE (1) DE69928000T2 (es)
ES (1) ES2247858T3 (es)
HU (1) HUP0104674A3 (es)
ID (1) ID29393A (es)
IL (1) IL143488A0 (es)
MX (3) MXPA01005641A (es)
NO (1) NO20012774L (es)
NZ (1) NZ527850A (es)
PL (1) PL349028A1 (es)
RU (1) RU2252772C2 (es)
TR (1) TR200101481T2 (es)
WO (3) WO2000033857A1 (es)
ZA (1) ZA200104611B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091558A1 (en) * 2002-08-12 2004-05-13 Lonza, Inc. Antimicrobial compositions
US20060241084A1 (en) * 2002-10-11 2006-10-26 The Hospital For Sick Children Inhibition of vascular endothelial growth factor
US20080015249A1 (en) * 1998-12-07 2008-01-17 Ecosmart Technologies, Inc. Cancer treatment compositions and method using natural plant essential oils

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113513A1 (de) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10259619A1 (de) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
MD2231C2 (ro) * 2003-03-05 2004-02-29 Ион КАЛМЫК Compozitie pentru tratamentul patologiilor oncologice
US20060263403A1 (en) * 2003-04-24 2006-11-23 Essam Enan Compositions and methods for controlling insects involving the tyramine receptor
US7541155B2 (en) 2003-04-24 2009-06-02 Tyratech, Inc. Methods of screening compositions for potential insect control activity
US7622269B2 (en) 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
AU2004253582B2 (en) * 2003-07-02 2011-02-10 Genentech, Inc. TRP-P8 active compounds and therapeutic treatment methods
DE10341933A1 (de) * 2003-09-11 2005-04-14 Lts Lohmann Therapie-Systeme Ag Medizinische Hautpflaster mit einem Gehalt an ätherischen Ölen zur Behandlung von Erkältungskrankheiten, sowie Verfahren für deren Herstellung
SE0401302D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of erk-phosphorylation
WO2006120495A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
US20090035403A2 (en) * 2005-06-16 2009-02-05 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
CN100553628C (zh) * 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
WO2008003007A2 (en) * 2006-06-27 2008-01-03 Tyratech, Inc. Compositions and methods for treating parasitic infections
US8685471B2 (en) * 2006-07-17 2014-04-01 Tyratech, Inc. Compositions and methods for controlling insects
MX2009007637A (es) * 2007-01-16 2009-09-28 Tyratech Inc Composiciones y metodos para control de pestes.
JP2011021013A (ja) * 2009-06-19 2011-02-03 Ube Industries Ltd オキシル基を有する芳香族メチルアルコール化合物の製造方法
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
US8003393B1 (en) * 2010-02-09 2011-08-23 Panasonic Corporation Method for determining whether or not a mammal is affected with a lung cancer
WO2012006563A2 (en) 2010-07-08 2012-01-12 The Administrators Of The Tulane Educational Fund Novel daidzein analogs as treatment for cancer
FR2967055B1 (fr) * 2010-11-08 2012-12-21 Biochimie Appliquee Solabia Compositions cosmetiques a base d'esters de piperonyle et leur utilisation en sosmetique en tant qu'anti-vieillissement cutane et agent depigmentant
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
EP2714021A1 (en) * 2011-02-02 2014-04-09 Max Reynolds Composition of monoterpenoids having bactericidal properties
WO2012177799A1 (en) * 2011-06-20 2012-12-27 Atheronova Operations, Inc. Subcutaneous fat reduction
IN2014MN00808A (es) 2011-11-03 2015-09-04 Unilever Plc
KR101357395B1 (ko) 2012-08-06 2014-02-05 영남대학교 산학협력단 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
WO2015102448A1 (ko) * 2014-01-03 2015-07-09 전북대학교 산학협력단 신남알데히드 및 퀴논 메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
US9950071B2 (en) * 2014-01-03 2018-04-24 Industrial Cooperation Foundation Chonbuk National University Hybrid anticancer prodrug simultaneously producing cinnamaldehyde and quinone methide and method for preparing same
JP6669665B2 (ja) * 2014-03-20 2020-03-18 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 体重管理にシンナムアルデヒド及び亜鉛を用いるための方法及び組成物
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US20160106722A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
DE202015106125U1 (de) * 2015-10-23 2016-10-27 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige Zusammensetzung zur Behandlung von Tumor- und/oder Krebserkrankungen
CN105294465A (zh) * 2015-12-08 2016-02-03 天津医科大学 一种抗乳腺癌转移作用的手性紫罗兰酮生物碱衍生物及医药用途
CN105559074B (zh) * 2016-02-03 2019-02-12 华南农业大学 一种茶叶挥发性精油在制备防癌保健品或抗癌药物中的应用
KR101798203B1 (ko) * 2016-09-23 2017-11-15 전북대학교 산학협력단 산성 pH 및 에스테라아제에 의해 신남알데히드 및 퀴논메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
RU2020135149A (ru) 2018-04-06 2022-05-06 Уцар Хелс ГМбХ Лечение рака производными гуанидиния
CN109112106B (zh) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 人原代肝癌组织的体外模型的建立方法
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022069013A1 (fr) * 2020-10-04 2022-04-07 Omar Bencherguia Composition médicamenteuse pour le traitement et la prévention du covid-19 et autres infections et affections nouvelles applications de l'alpha-acetoxytoluène, l'alcool benzylique et les groupes benzyle dans la lutte contre la pandémie covid-19 et autres infections et affections
CN119488512A (zh) * 2024-12-18 2025-02-21 澳门大学 肉桂醇及其衍生物在制备预防或治疗肿瘤的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS57106697A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
FR2557452B1 (fr) * 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
DE3515253C1 (de) * 1985-04-27 1986-06-19 Werner 6780 Pirmasens Walter Verwendung von isopropanolischen Lösungen von Diphenyl als topisches Arzneimittel
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3829200A1 (de) * 1988-08-29 1990-03-01 Kaempgen Dieter Dr Phil Wirkstoffe gegen die immunschwaeche-krankheit aids
JP2746453B2 (ja) * 1990-03-13 1998-05-06 鐘紡株式会社 活性酸素消去剤
EP0650723A3 (en) 1990-03-23 1995-08-30 Nippon Kayaku Kk New pharmaceutical uses of forskolin derivatives.
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
FR2683454B1 (fr) 1991-11-13 1995-06-09 Pf Medicament Composition pharmaceutique bactericide.
AU3123193A (en) * 1991-12-13 1993-07-19 G.D. Searle & Co. Transdermal azidothymidine
ATE142523T1 (de) * 1992-04-29 1996-09-15 Nordica Spa Bremsvorrichtung an rollschuh
CA2136233C (en) * 1992-05-19 2004-03-30 Graham Edmund Kelly Health supplements containing phyto-oestrogens, analogues or metabolites thereof
FR2697133B1 (fr) * 1992-10-28 1995-01-13 Transbiotech Composition biocide et/ou biostatique et ses applications.
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
JP3263481B2 (ja) 1993-05-19 2002-03-04 三洋電機株式会社 半導体装置および半導体装置の製造方法
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
RU2088245C1 (ru) * 1993-07-07 1997-08-27 Научно-исследовательский институт онкологии им.проф.Н.Н.Петрова Способ профилактики повышенного онкологического риска
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RU2102947C1 (ru) * 1994-01-12 1998-01-27 Любовь Сергеевна Кондаурова Средство для лечения заболеваний переднего отрезка глаза
RU2088247C1 (ru) * 1994-01-31 1997-08-27 Фонд содействия исследованиям и инициативам граждан по оздоровлению человека и среды им.Караваева В.В. Способ повышения эффективности лучевой терапии
US5626854A (en) 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
HUP0002049A2 (hu) * 1997-03-04 2000-10-28 Wisconsin Alumni Research Foundation Tumornövekedés megakadályozására szolgáló eljárás izoprenoidok és sztatinok kombinációk alkalmazásával
WO1998048790A1 (en) 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
JP2001510168A (ja) * 1997-07-18 2001-07-31 ノボ ノルディスク アクティーゼルスカブ ＦＶＩＩａ媒介性細胞内シグナル伝達経路に関連する反対条件の処理のためのＦＶＩＩａ又はＦＶＩＩａｉの使用
EP1063960A1 (en) * 1998-03-20 2001-01-03 The Procter & Gamble Company Composition for aroma delivery
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
ATE245430T1 (de) * 1998-10-23 2003-08-15 Dieter Ebert Zusammensetzung enthaltend eugenol und polyphenole, verwendung einer solchen zusammensetzung zur wundheilung
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2002531512A (ja) * 1998-12-07 2002-09-24 エコスマート テクノロジーズ，インコーポレーテッド 天然植物精油を用いた癌治療薬配合物および方法
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080015249A1 (en) * 1998-12-07 2008-01-17 Ecosmart Technologies, Inc. Cancer treatment compositions and method using natural plant essential oils
US20040091558A1 (en) * 2002-08-12 2004-05-13 Lonza, Inc. Antimicrobial compositions
US20090175966A1 (en) * 2002-08-12 2009-07-09 Lonza Inc. Antimicrobial compositions
US20090191289A1 (en) * 2002-08-12 2009-07-30 Lonza Inc. Antimicrobial compositions
US8784910B2 (en) 2002-08-12 2014-07-22 Lonza Inc. Antimicrobial compositions
US20060241084A1 (en) * 2002-10-11 2006-10-26 The Hospital For Sick Children Inhibition of vascular endothelial growth factor

Also Published As

Publication number Publication date
US20040156922A1 (en) 2004-08-12
NO20012774D0 (no) 2001-06-06
RU2252772C2 (ru) 2005-05-27
AU2167000A (en) 2000-06-26
CA2353476A1 (en) 2000-06-15
EP1137426A1 (en) 2001-10-04
WO2000033858A1 (en) 2000-06-15
ZA200104611B (en) 2001-12-13
KR20010080692A (ko) 2001-08-22
US6812258B2 (en) 2004-11-02
AR020019A1 (es) 2002-03-27
WO2000033857A1 (en) 2000-06-15
CN1329498A (zh) 2002-01-02
JP2002531511A (ja) 2002-09-24
DE69928000D1 (de) 2005-12-01
MXPA01005545A (es) 2003-07-14
CA2353516A1 (en) 2000-06-15
US7008649B2 (en) 2006-03-07
CN100448454C (zh) 2009-01-07
MXPA01005641A (es) 2003-07-14
AR020021A1 (es) 2002-03-27
HUP0104674A3 (en) 2003-01-28
US20080015249A1 (en) 2008-01-17
US20040146595A1 (en) 2004-07-29
US20030108622A1 (en) 2003-06-12
US20020182268A1 (en) 2002-12-05
JP2002531512A (ja) 2002-09-24
TR200101481T2 (tr) 2001-09-21
ATE307601T1 (de) 2005-11-15
DE69928000T2 (de) 2006-06-08
NZ527850A (en) 2004-07-30
US20030108623A1 (en) 2003-06-12
EP1137426B1 (en) 2005-10-26
US20030017218A1 (en) 2003-01-23
JP2002531513A (ja) 2002-09-24
WO2000033856A1 (en) 2000-06-15
ES2247858T3 (es) 2006-03-01
AU2167100A (en) 2000-06-26
ID29393A (id) 2001-08-30
WO2000033857A9 (en) 2001-12-13
PL349028A1 (en) 2002-07-01
US7291650B2 (en) 2007-11-06
MXPA01005598A (es) 2003-07-14
NO20012774L (no) 2001-06-06
CA2353475A1 (en) 2000-06-15
IL143488A0 (en) 2002-04-21
EP1137425A1 (en) 2001-10-04
AR020020A1 (es) 2002-03-27
HUP0104674A2 (en) 2002-06-29
CZ20011979A3 (cs) 2001-10-17
BR9916879A (pt) 2001-11-06
AU1841900A (en) 2000-06-26
EP1137427A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
US7008649B2 (en) Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
US11090275B2 (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
Im et al. Epigallocatechin-3-gallate suppresses IGF-I-induced lipogenesis and cytokine expression in SZ95 sebocytes
US20220054429A1 (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
US20240325345A1 (en) Methods of increasing effects of the ingestion of drugs such as cannabis or 5ht2 agonists via applications with 5ht1/2, CB1, opiate allosteric modulators as/in foods, beverages, vaporizer, smoking and supplement products/formulations.
Kim et al. Therapeutic effect of guggulsterone in primary cultured orbital fibroblasts obtained from patients with graves’ orbitopathy
Ross Cannabis and Cancer
EP4422611A1 (en) Methods of treating head and neck cancers with hemp extract
Power et al. The Potential Roles of Seeds and Seed Bioactives on the Prevention and Treatment of Breast and Prostate Cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: ECOSMART TECHNOLOGIES, INC., TENNESSEE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BESSETTE, STEVEN M.;ENAN, ESSAM E.;REEL/FRAME:010646/0001

Effective date: 20000216

AS Assignment

Owner name: AMSOUTH BANK, TENNESSEE

Free format text: SECURITY INTEREST;ASSIGNOR:ECOSMART TECHNOLOGIES, INC.;REEL/FRAME:011944/0001

Effective date: 20010604

AS Assignment

Owner name: CARELL, JAMES W., TENNESSEE

Free format text: SECURITY INTEREST;ASSIGNOR:ECOSMART TECHNOLOGIES, INC.;REEL/FRAME:012418/0824

Effective date: 20020226

AS Assignment

Owner name: AMSOUTH BANK, TENNESSEE

Free format text: FULL RELEASE OF SECURITY INTEREST;ASSIGNOR:ECOSMART TECHNOLOGIES, INC.;REEL/FRAME:012581/0176

Effective date: 20020328

AS Assignment

Owner name: ECOSMART TECHNOLOGIES, INC., TENNESSEE

Free format text: FULL RELEASE OF SECURITY INTEREST RECORDED ON FEBRUARY 26, 2002 AT REEL/FRAME 012418/0824.;ASSIGNOR:CARELL, JAMES W.;REEL/FRAME:013570/0350

Effective date: 20030325

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION